OLMA

OlemaD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Base case

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Most likely

B-

Bear case

Probability

Target price

$3.50

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-02

AI commentary

Cautious monitoring view, consistent with the packet's negative directional prior and limited coverage. A stored third-party article reported a 15.1% premarket fall on September 14 following SERENA-4; that is not a verified closing-price reaction. Roche's October 1 evERA update complicates a uniformly negative oral-SERD read-through, but no Olema-specific price reaction to it was verified. Analyst-revision coverage is thin. Social, options, short-interest and employee measures were not supplied; their zero entries denote unavailable data, not neutral readings. The August 13 8-K note establishes a filing date but supplies no substantive operating update [#8-K-2026-08-13].

RankAlpha Sentiment Codex - 2026-10-02

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-10-31catalystOral-SERD competitor read-throughMedium impact

AstraZeneca's first-line SERENA-4 combination trial missed its primary endpoint, while Roche reported positive results for its distinct later-line evERA combination trial. These results may influence sentiment but do not establish the outcome of Olema's palazestrant monotherapy trial [#PR-AZN-2026-09-11] [#PR-ROCHE-2026-10-01]. Sources: https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html and https://www.roche.com/media/releases/med-cor-2026-10-01

2026-12-31catalystOP-3136 and Bayer study initiationMedium impact

Olema anticipated starting enrollment in a Phase 1b/2 study of OP-3136 plus darolutamide in Q4 2026. Initiation would demonstrate development execution, not clinical efficacy [#SEC-8K-2026-08-10].

2027-03-31eventOPERA-01 Phase 3 top-line dataHigh impact

Olema completed enrollment and expects top-line data for palazestrant monotherapy in second- or third-line ER-positive, HER2-negative metastatic breast cancer in Q1 2027. Efficacy and safety are the principal binary value drivers. March 31 marks the end of the company's stated window, not an announced release date; the probability estimates a readout within that window, not trial success [#SEC-8K-2026-08-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-02 • Updated nightlySource: Internal modelMethodology